Skip to content
Rio de Janeiro · São Paulo · Salvador — matters across Brazil
Bruno Marcelos — Escritório de Advocacia

Pauta Regulatória · Daily brief

No. 217

Automatically translated from the Portuguese edition, which prevails in case of discrepancy. Ler em português

Federal Official Gazette

OPERATING AUTHORIZATION

On this date, Operating Authorization is granted to the Health Care Plan Operators listed below, after the Directorate of Standards and Qualification of Operators (DIOPE) and the Directorate of Standards and Qualification of Products (DIPRO) concluded their analysis of the Operating Authorization proceedings, pursuant to Normative Resolution (RN) No. 543, of September 2, 2022, and its subsequent amendments.

Corporate Name

Operator Registration

Case Number

ELOSAÚDE ASSISTÊNCIA MÉDICA LTDA.

42494-3

33910.015118/2026-76

ANS news

Integration between SUS and supplementary health, focused on the person and on value in health, is highlighted at FGV seminar

Wadih Damous stressed the need to reduce barriers between the public and private networks, improve information management and assess results based on the outcomes that matter to citizens

https://www.gov.br/ans/pt-br/assuntos/noticias-1/periodo-eleitoral/integracao-entre-sus-e-saude-suplementar-com-foco-na-pessoa-e-em-valor-em-saude-ganha-destaque-em-seminario-da-fgv

ANS Chief Executive Officer highlights the importance of combating fraud in the medical devices sector

Wadih Damous advocated greater transparency in the relationships among the different players and the strengthening of mechanisms to prevent irregularities

https://www.gov.br/ans/pt-br/assuntos/noticias-1/periodo-eleitoral/diretor-presidente-da-ans-destaca-importancia-do-combate-a-fraudes-no-setor-de-dispositivos-medicos

Open public consultations

  • CP 175. Subject: criticism and suggestions regarding the preliminary recommendations not to incorporate the technologies covered by UAT No. 199 – Cholangioscopy, UAT No. 200 – Next-generation sequencing (NGS) panel and UAT No. 206 – Tepotinib hydrochloride. Deadline: Aug 12, 2026 to Aug 31, 2026

Scheduled public hearings

No public hearings are scheduled.

Open public calls for input

There is no open public call for input.

Open public calls

There are no open public calls

Other news

Small and medium-sized health operators need differentiated treatment from ANS, says Abramge president

Source: brasil247.com · read the full article

Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.